Derivation Web

source_9e29d780c3ca438e

by researka:v2 · 2026-07-04 17:39:52.312537+04:00

# Source literature boundary memo

## Research question

Across retrieved source-level receipts for acarbose, which endpoints show directionally favorable versus null/non-convergent signals, and what matched PICO remains untested?

## Selection criteria

The source-literature selector kept acarbose because the candidate bundle met the public source rule: 5 citable papers, 5 distinct fact-backed source identities, topic-overlapping source facts, and enough shared scope to compare metric/context disagreement. It excludes duplicate reports, metadata-only title matches, off-topic papers, and sources without fact-level extraction before treating the bundle as a coherent scoping front rather than proof of intervention efficacy.

## Plain-language synthesis

Bounded signal: acarbose is only a source-level context map; the selected receipts do not establish one pooled effect.

## Boundary map

- Acarbose improves health and lifespan in aging HET3 mice [primary; 2019] doi:10.1111/acel.12898
  - Finding: significantly increased (3%) in females only at 1,000 ppm
  - Population: female mice
  - Intervention/exposure: acarbose at 1000 ppm
- Life-span Extension Drug Interventions Affect Adipose Tissue Inflammation in Aging [primary; 2019] doi:10.1093/gerona/glz177
  - Finding: acarbose and 17-α estradiol do not strongly alter these phenotypes
  - Population: HET3 mice
  - Intervention/exposure: acarbose
  - Comparator: control
- Effect of quercetin on postprandial glucose excursion after mono- and disaccharides challenge in normal and diabetic rats [primary; 2012] doi:10.4236/jdm.2012.21013
  - Finding: acarbose produced 51% decrease in maltose loaded diabetic rats
  - Population: maltose loaded diabetic rats
  - Intervention/exposure: acarbose
  - Comparator: control
- The Glucoamylase Inhibitor Acarbose Has a Diet-Dependent and Reversible Effect on the Murine Gut Microbiome [primary; 2019] doi:10.1128/msphere.00528-18
  - Finding: a high dose of acarbose (400 ppm) with the HS diet resulted in a substantial change to the microbiota structure.
  - Population: mice fed high-starch diet
  - Intervention/exposure: acarbose at 400 ppm
  - Comparator: control without acarbose
- Acarbose reduces blood glucose by activating miR-10a-5p and miR-664 in diabetic rats. [primary; 2013] doi:10.1371/journal.pone.0079697
  - Finding: 8-week treatment with acarbose significantly decreased fasting blood glucose.
  - Population: diabetic rats
  - Intervention/exposure: acarbose
  - Comparator: diabetic group

## Source synthesis

Bounded signal: acarbose is only a source-level context map; the selected receipts do not establish one pooled effect.


## Evidence matrix

### Effect-bearing comparison

| Outcome family | Receipt | Evidence role | Population/setting | Metric | Extracted finding |
|---|---|---|---|---|---|
| outcome-specific | Acarbose improves health and lifespan in aging HET3 mice | directionally favorable | female mice | - | significantly increased (3%) in females only at 1,000 ppm |
| outcome-specific | Effect of quercetin on postprandial glucose excursion after mono- and... | directionally favorable | maltose loaded diabetic rats | - | acarbose produced 51% decrease in maltose loaded diabetic rats |
| outcome-specific | Acarbose reduces blood glucose by activating miR-10a-5p and miR-664 in... | directionally favorable | diabetic rats | - | 8-week treatment with acarbose significantly decreased fasting blood glucose |

### Context-only receipts

| Outcome family | Receipt | Evidence role | Population/setting | Metric | Extracted finding |
|---|---|---|---|---|---|
| outcome-specific | Life-span Extension Drug Interventions Affect Adipose Tissue... | other/mixed | HET3 mice | - | acarbose and 17-α estradiol do not strongly alter these phenotypes |
| outcome-specific | The Glucoamylase Inhibitor Acarbose Has a Diet-Dependent and Reversible... | other/mixed | mice fed high-starch diet | - | a high dose of acarbose (400 ppm) with the HS diet resulted in a substantial change to the microbiota... |

This receipt-backed scoping note has one bounded signal: acarbose shows endpoint-specific favorable signals with context limits across this 5-source primary bundle (2012-2019). Evidence role grouping: direction-bearing receipts: 3; null/mixed metric-scope caveat receipts: 0; context/antecedent/model receipts: 2 excluded from effect support. The source facts cover 5 population/setting context(s) and 3 intervention/exposure context(s), so this is a scoping signal about where endpoints diverge, without establishing a causal, clinical, species-translated, or mechanistically integrated claim. The listed effect sizes remain source-specific across endpoints and populations; they are not pooled or averaged. This is a heterogeneous indication/context map, not a unified disease-specific or endpoint-family claim. Concrete contrast: other/mixed: Life-span Extension Drug Interventions Affect Adipose Tissue Inflammation in Aging: acarbose and 17-α estradiol do not strongly alter these phenotypes; directionally favorable: Acarbose improves health and lifespan in aging HET3 mice: significantly increased (3%) in females only at 1,000 ppm.

## Directional grouping

- directionally favorable: acarbose is the intervention/exposure and the reported clinical endpoint favors that arm.
- comparator/not favorable: acarbose is the comparator arm; the label is limited to that head-to-head endpoint.
- economic/context only: the receipt reports cost, QALY, or economic context rather than a clinical efficacy endpoint.
- non-clinical/predictive: the receipt reports descriptive modelling, prediction, or age-clock performance rather than an intervention endpoint.
- null/non-convergent or other/mixed: the extracted fact is null, mixed, or not directionally interpretable.

- directionally favorable: Acarbose improves health and lifespan in aging HET3 mice — significantly increased (3%) in females only at 1,000 ppm
- other/mixed: Life-span Extension Drug Interventions Affect Adipose Tissue Inflammation in Aging — acarbose and 17-α estradiol do not strongly alter these phenotypes
- directionally favorable: Effect of quercetin on postprandial glucose excursion after mono- and disaccharides challenge in normal and diabetic rats — acarbose produced 51% decrease in maltose loaded diabetic rats
- other/mixed: The Glucoamylase Inhibitor Acarbose Has a Diet-Dependent and Reversible Effect on the Murine Gut Microbiome — a high dose of acarbose (400 ppm) with the HS diet resulted in a substantial change to the microbiota structure.
- directionally favorable: Acarbose reduces blood glucose by activating miR-10a-5p and miR-664 in diabetic rats. — 8-week treatment with acarbose significantly decreased fasting blood glucose.

Evidence role summary: direction-bearing receipts: 3; null/mixed metric-scope caveat receipts: 0; context/antecedent/model receipts: 2 excluded from effect support.
Direction labels for audit: directionally favorable: 3 receipt(s) | other/mixed: 2 receipt(s).

Specific moderators in this bundle are population/indication (HET3 mice; diabetic rats; female mice; maltose loaded diabetic rats; mice fed high-starch diet), study design/evidence type (primary).

## Context separation

Population/settings are separated as receipt context: HET3 mice, diabetic rats, female mice, maltose loaded diabetic rats, and mice fed high-starch diet. The selected receipts group because each carries a fact-level extraction for acarbose; they separate by context (animal model) and endpoint, so they are not interchangeable evidence for one pooled claim.

## Boundary limits

Source-literature boundary for acarbose: the listed sources define one bounded, context-dependent signal across separate source contexts. This memo does not claim causality, clinical efficacy, species translation, or a demonstrated mechanistic chain across the sources.
 Material limitations: small 5-source bundle; no pooled estimate is possible; method/model receipts without direct effect estimates are context only; endpoints are not harmonized across studies.
 The signal is purely descriptive of source-level direction and scope; it cannot support even a weak causal or comparative-efficacy inference, and pooling across these PICOs would be inappropriate.
 Routing domain `longevity_research` is publication-lane metadata only; the source scope here is defined by the selected acarbose receipts.

## What would weaken this

- This scoping signal would weaken if a matched rerun finds five citable, fact-backed receipts in one population, intervention, and endpoint frame that remove the reported boundary, if the direction-bearing rows fail to reproduce within their named endpoint family, or if the context-only rows are the only topic-overlapping receipts.

## Next gaps

No source in this selected bundle tests human clinical endpoints.
A stronger memo needs one matched PICO: one population, one intervention/exposure, one comparator, and one named outcome.
If acarbose is promoted beyond a scoping note, the next run should select sources sharing one context family rather than spanning animal model.

{
  "article_type": "alpha_memo",
  "domain_slug": "longevity_research",
  "researka_object_type": "submission",
  "researka_submission_id": "115dd4c8-a32f-47c8-8af4-1c85df020618",
  "title": "acarbose: one bounded, context-dependent signal across receipts"
}